MANKIND vs MEDICAMEQ: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. MANKIND PHARMA shows a higher ROE, a higher ROCE and a higher net margin, while MEDICAMEQ shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MANKIND leads 5; MEDICAMEQ leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Live Price | ₹2,275.6 | ₹346.3 |
| Day Change | -0.43% | 0.23% |
| Volume | 6.5 L | 1.29 L |
| 52-Week High | ₹2,642 | ₹447.65 |
| 52-Week Low | ₹1,909.7 | ₹212.4 |
| Distance from 52W High | -13.87% | -22.64% |
Valuation
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Market Cap | ₹94,042 Cr | ₹362 Cr |
| P/E Ratio | 45.88x | 36.16x |
| P/B Ratio | 5.77x | 1.42x |
| EPS | ₹13.9 | ₹1.56 |
| Book Value | ₹401 | ₹203.17 |
| Dividend Yield | 0% | 0.37% |
Growth
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.8% | 80.2% |
| EPS Growth (TTM YoY) | 31.7% | 44.7% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| ROE | 12.41% | 3.36% |
| ROCE | 11.87% | 4.09% |
| Net Margin | 13.34% | 5.21% |
| Operating Margin | 27.68% | 8.01% |
| Debt to Equity | 0.34x | 0.13x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Promoter Holding | 72.62%▼ 0.01 pp | 40.46% |
| FII Holding | 9.37%▼ 0.08 pp | 0.07%▼ 0.03 pp |
| DII Holding | 15.56%▲ 0.17 pp | 0.4%▲ 0.4 pp |
| Public Holding | 2.45%▼ 0.08 pp | 59.02%▼ 0.37 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MANKIND PHARMA and MEDICAMEQ.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.